Considerable progress has been made in identifying the molecules involved in promoting glioma migration and invasion. Although many anti-proliferative and proapoptotic therapeutic strategies have been employed, less headway has been made with targeting the molecules involved in invasion. Those that have been used have not been very successful. Importantly, the complex interactions between the different classes of proteins involved in invasion are better delineated and this will hopefully provide the basis for a more successful, multi-targeted approach to the inhibition of this phenotype.


1. Scherer, H. D. (1940). Cerebral astrocytomas and their derivatives. Am J Cancer 1, 9-198.

2. Burger, P. C., Heinz, E. R., Shibata, T., and Kleihues, P. (1988). Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68, 698-704.

3. Kelly, P. J., Daumas-Duport, C., Scheithauer, B. W., Kall, B. A., and Kispert, D. B. (1987). Stereotactic histologic correlations of computed tomography and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 62, 450-459.

4. Johnson, P. C., Hunt, S. J., and Drayer, B. P. (1989). Human cerebral gliomas. Correlation of postmortem MR imaging and neuropathologic findings. Radiology 170, 211-217.

5. Burger, P. C. (1987). The anatomy of astrocytomas. Mayo Clin Proc 62, 527-529.

6. Burger, P. C., and Kleihues, P. (1989). Cytologic composition of the untreated glioblastoma with implications for evaluation and needle biopsies. Cancer 63, 2014-2023.

7. Giangaspero, F., and Burger, P. C. (1983). Correlations between cytologic composition and biologic behavior in the glioblastoma multiforme: A postmortem study of 50 cases. Cancer 52, 2320-2333.

8. Burger, P. C. (1990). Classification, grading, and patterns of spread of malignant gliomas. In Malignant cerebral glioma (M. V. J. Apuzzo, Ed.), pp. 3-17. American Association of Neurosurgeons.

9. Schiffer, D. (1986). Neuropathology and imaging: the ways in which glioma spreads and varies in its histological aspect.

In Biology of brain tumour (M. D. Walker and D. G. T. Thomas, Eds.), pp. 163-172. Boston: Nijhoff.

10. Choucair, A. K., Levin, V. A., Gutin, P. H. et al. (1986). Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65, 654-658.

11. Hochberg, F. H., and Pruitt, A. (1980). Assumptions in the radiotherapy of glioblastoma. Neurology 30, 907-911.

12. Awad, I. A. (1987). Spread of malignant gliomas [letter]. J Neurosurg 66, 946-947.

13. Bashir, R., Hochberg, F., and Oot, R. (1988). Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23, 27-30.

14. Wallner, K. E., Galicich, J. H., Krol, G., Arbit, E., and Malkin, M. G. (1989). Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16, 1405-1409.

15. Liang, B. C., Thornton, A. F., Jr., Sandler, H. M., and Greenberg, H. S. (1991). Malignant astrocytomas: Focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 25, 559-563.

16. Garden, A. S., Maor, M. H., Yung, W. K. A. et al. (1991). Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 20, 99-110.

17. Tsuboi, K., Yoshii, Y., Nakagawa, K., and Maki, Y. (1986). Regrowth patterns of supratentorial gliomas. Estimation from computed tomographic scans. Neurosurgery 19, 946-951.

18. Giese, A., Bjerkvig, R., Berens, M. E., and Westphal, M. (2003). Cost of migration: Invasion of malignant gliomas and implications for treatment. J Clin Oncol 21, 1624-1636.

19. Joy, A. M., Beaudry, C. E., Tran, N. L. et al. (2003). Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 116, 4409-4417.

20. Gladson, C. L. (1999). The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 58, 1029-1040.

21. Kresse, H., and Schonherr, E. (2001). Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 189, 266-274.

22. Jaworski, D. M., Kelly, G. M., and Hochfield, S. (1994). BEHAB, a new member of the proteoglycan tandem repeat family of hyaluronan-binding proteins that is restricted to the brain. J Cell Biol 125, 495-509.

23. Jaworski, D. M., Kelly, G. M., Piepmeier, J. M., and Hochfield, S. (1996). BEHAB (brain-enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res 56, 2293-2298.

24. Zhang, H., Kelly, G., Zerillo, C., Jaworski, D. M., and Hochfield, S. (1998). Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion in vivo. J Neurosci 18, 2370-2376.

25. Viapiano, M. S., Mattews, R. T., and Hockfield, S. (2003). A novel membrane-associated glycovariant of BEHAB/ brevican is upregulated during rat brain development and in a rat model of invasive glioma. J Biol Chem 278, 33239-33247.

26. Paulus, W., Baur, I., Dours-Zimmermann, M. T., and Zimmermann, D. R. (1996). Differential expression of versican isoforms in brain tumors. J Neuropathol Exp Neurol 55, 528-533.

27. Wu, Y., Chen, L., Cao, L., Sheng, W., and Yang, B. B. (2004). Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and ^1-integrin. J Cell Sci 117, 2227-2237.

28. Preobrazhensky, A. A., Oohira, A., Maier, G., Veronina, A. S., Vovk, T. S., and Barabanov, V. M. (1997). Identification of monoclonal antibody At5 as a new member of NHK-1 antibody family: the reactivity with myelin-associated glycoprotein and with two brain-specific proteoglycans, phosphacan and neuro-can. Neurochem Res 22, 133-140.

29. Grumet, M., Milev, P., Sakurai, T. et al. (1994). Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of the central nervous tissue. J Cell Biol 269, 12142-12146.

30. Bertolotto, A., Magrassi, M. L., Orsi, L., and Schiffer, D. (1986). Glycosaminoglycan changes in human gliomas. J Neurooncol 4, 43-48.

31. Annabi, B., Thibault, S., Moumdjian, R., and Beliveau, R. (2004). Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells. J Biol Chem 279, 21888-21896.

32. Ward, J. A., Huang, L., Guo, H., Ghatak, S., and Toole, B. P. (2003). Perturbation of hyaluronan interactions inhibits malignant properties of gliomas cells. Am J Pathol 162, 1403-1409.

33. Bellail, A. C., Hunter, S. B., Brat, D. J., Tan, C., and Van Meir, E. G. (2004). Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36, 1046-1069.

34. Gladson, C. L., and Cherish, D. A. (1991). Glioblastoma expression of vitronectin and the av^3 integrin: adhesion mechanism for transformed glial cells. J Clin Invest 88, 1924-1932.

35. Gladson, C. L., Wilcox, J. N., Sanders, L., Gillespie, G. Y., and Cherish, D. A. (1995). Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci 108, 947-956.

36. Chavakis, T., Kanse, S. M., Yutzy, B., Lijnen, R., and Preissner, K. T. (1998). Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 91, 2305-2312.

37. Rosenblatt, S., Bassuk, J. A., Alpers, C. E., Sage, E. H., Timpl, R., and Preissner, K. T. (1997). Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM-40, SPARC). Biochem J 324, 311-319.

38. Tysnes, B. B., Mahesparan, R., Thorsen, F. et al. (1999). Laminin expression by glial fibrillary acidic protein positive cells in human gliomas. Int J Dev Neurosci 17, 531-539.

39. Ljubimova, J. Y., Fugita, M., Khazenzon, N. M. et al. (2004). Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer 101, 604-612.

40. Mahesparan, R., Read, T.-A., Lund-Johansen, M., M., Skaft-nesmo, K. O., Bjerkvig, R., and Engebraaten, O. (2003). Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol (Berl) 105, 49-57.

41. Fukushima, Y., Ohnishi, T., Arita, N., Hayakawa, T., and Sekiguchi, K. (1998). Integrin a3^1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells. Int J Cancer 76, 63-72.

42. Tysnes, B. B., Larsen, L. F., Ness, G. O. et al. (1996). Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies. Int J Cancer 67, 777-784.

43. Chintala, S. K., Sawaya, R., Gokaslan, Z. L., Fuller, G., and Rao, J. S. (1996). Immunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro. Cancer Lett 101, 107-114.

44. McComb, R. D., Moul, J. M., and Bigner, D. D. (1987). Distribution of type IV collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein. J Neuropathol Exp Neurol 46, 623-633.

45. Higuchi, M., Ohnishi, T., Arita, N., Hiraga, S., and Hasyakawa, T. (1993). Expression of tenascin in human gliomas: its relation to histological malignancy, tumor differentiation, and angio-genesis. Acta Neuropathol (Berl) 85, 481-487.

46. Lukas, Z., and Dvorak, K. (2004). Adhesion molecules in biology and oncology. Acta Vet BRNO 73, 93-104.

47. Sasaki, H., Yoshida, K., Ikeda, E. et al. (1998). Expression of the neural cell adhesion molecule in astrocytic tumors: an inverse correlation with malignancy. Cancer 82, 1921-1931.

48. Prag, S., Lepekhin, E. A., Kolkova, K. et al. (2002). NCAM regulates cell motility. J Cell Sci 115, 283-292.

49. Edvardsen, K., Pedersen, P. H., Bjerkvig, R. et al. (1994). Transfection of glioma cells with the neural-cell adhesion molecule NCAM: effect on glioma-cell invasion and growth in vivo. Int J Cancer 58, 116-122.

50. Maidment, S. L., Ruckledge, G. J., Roopai, H. K., and Pilkington, G. J. (1997). An inverse correlation between expression of NCAM-A and the matrix metalloproteinases gelatinase-A and gelatinase-B in human glioma cells in vitro. Cancer Lett 116, 71-77.

51. Sehgal, A., Boynton, A. L., Young, R. F. et al. (1998). Cell adhesion molecule Nr-CAM is overexpressed in human brain tumors. Int J Cancer 76, 451-458.

52. Sehgal, A., Ricks, S., Warrick, J., Boynton, A. L., and Murphy, G. P. (1999). Anti-sense human neuroglia related cell adhesion molecule hNr-CAM, reduces the tumorigenic properties of human glioblastoma cells. Anticancer 19, 4947-4953.

53. Boon, K., Edwards, J. B., Eberhart, C. G., and Riggins, G. J. (2004). Identification of astrocytoma associated genes including cell surface markers. BMC Cancer 4, 39.

54. Maepaa, A., Kovanen, P. E., Patau, A., Jaaskelainen, J., and Timonen, T. (1997). Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain. Acta Neuropathol (Berl) 94, 216-225.

55. Gringas, M. C., Roussel, E., Bruner, J. M., Branch, C. D., and Moser, R. P. (1995). Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 57, 143-153.

56. Shinoura, N., Paradies, N. E., Warnick, R. E. et al. (1995). Expression of N-cadherin and alpha-catenin in astrocytomas and glioblastomas. Br J Cancer 72, 627-633.

57. Asano, K., Kubo, O., Tajika, Y. et al. (1997). Expression and role of cadherins in astrocytic tumors. Brain Tumor Pathol 14, 27-33.

58. Asano, K., Kubo, K., Tajika, Y., Takakur, K., and Suzuki, S. (2000). Expression of cadherin and CSF dissemination in malignant astrocytic tumors. Neurosurg Rev 23, 39-44.

59. Huang, Z. Y., Wu, Y., Hedrick, N., and Gutmann, D. H. (2003). T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21 (CIP/WAF1) expression. Mol Cell Biol 23, 566-578.

60. Vajkoczy, P., Blum, S., Lamparter, M. et al. (2003). Multistep nature of microvascular recruitment of ex vivo-expanded embryonic endothelial progenitor cells during tumor angiogen-esis. J Exp Med 197, 1755-1765.

61. Johnson, K. G., and Van Vactor, D. (2003) Receptor protein tyrosine phosphatases in nervous system development. Physiol Rev 83, 1-24.

62. Norman, S. A., Golfinos, J. G., and Scheck, A. C. (1998). Expression of a receptor protein tyrosine phosphatase in human glial tumors. J Neurooncol 36, 209-217.

63. Ulbricht, U., Brockmann, M. A., Aiger, A. et al. (2003). Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol 62, 1265-1275.

64. Muller, S., Kunkel, P., Lamzsus, K. et al. (2003). A role for receptor tyrosine phosphatase zeta in glioma cell migration. Oncogene 22, 6661-6668.

65. Adamsky, K., Schilling, J., Garwood, J., Faissner, A., and Peles, E. (2001). Glial cell adhesion is mediated by binding of the FNIII domain of receptor protein phosphatase jß^RPTPjß) to Tenascin-C. Oncogene 20, 609-618.

66. Tews, D. S. (2000). Adhesive and invasive features in gliomas. Pathol 196, 701-711.

67. Tews, D. S., and Nissen, A. (1998-1999). Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Invasion Metastasis 18, 271-284.

68. Camby, I., Belot, N., Lefranc, F. et al. (2002). Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61, 585-596.

69. Camby, I., Belot, N., Rorive, S. et al. (2001). Galectins are differentially expressed in supratentorial pilocytic astrocyto-mas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11, 12-26.

70. Schrappe, M., Klier, F. G., Spiro, R. C., Waltz, T. A., Reisfeld, R. A., and Gladson, C. L. (1991). Correlation of chrondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51, 4986-4993.

71. Murai, T., Miyazaki, Y., Nishinakamura, H. et al. (2004). Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J Biol Chem 279, 4541-4550.

72. Ranuncolo, S. M., Ladeda, V., Specterman, S. et al. (2002). CD44 expression in human gliomas. J Surg Oncol 79, 30-36.

73. Akiyama, Y., Jung, S., Salhia, B. et al. (2001). Haluronate receptors mediating glioma cell migration and proliferation. J Neurooncol 53, 115-127.

74. Yu, Q., and Stamenkovic, I. (1999). Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13, 35-48.

75. Monaghan, M., Mulligan, K. A., Gillespie, H. et al. (2000). Epidermal growth factor up-regulates CD44-dependent astro-cytoma invasion in vitro. J Pathol 192, 519-525.

76. Tsatas, D., Kanagasundaram, V., Kaye, A., and Novak, U. (2002). EGF receptor modifies cellular responses to hyaluronan in glioblastoma cell lines. J Clin Neurosci 9, 282-288.

77. Murphy-Ullrich, J. E. (2001). The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest 107, 785-790.

78. Troussard, A. A., Costello, P., Yoganathan, T. N., Kumagai, S., Roskelley, C. D., and Dedhar, S. (2000). The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metallopro-teinase 9 (MMP-9). Oncogene 19, 5444-5452.

79. Obara, S., Nakata, M., Takeshima, H. et al. (2004). Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398. Cancer Letters 208, 115-122.

80. Taga, T., Suzuki, A., Gonzalez-Gomez, I. et al. (2002). av-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98, 690-697.

81. Bornstein, P., and Sage, E. H. (2002). Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14, 608-616.

82. Sullivan, M. M., and Sage, E. H. (2004). Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/0steonectin family. Int J Biochem Cell Biol 36, 991-996.

83. Chen, H., Herndon, M. E., and Lawler, J. (2000). The cell biology of thrombospondin-1. Matrix Biol 19, 597-614.

84. Zamecnik, J., Vargova, L., Homola, A., Kodet, R., and Sykova, E. (2004). Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol. Appl Neurobiol 30, 338-350.

85. Zagzag, D., Friedlander, D. R., Miller, D. C. et al. (1995). Tenascin expression in astrocytomas correlates for angiogen-esis. Cancer Res 55, 907-914.

86. Rempel, S. A., Golembieski, W. A., Ge, S. et al. (1998). SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 57, 1112-1121.

87. Rempel, S. A., Ge, S., and Gutierrez, J. A. (1999). SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 5, 237-241.

88. Saitoh, Y., Kuratsu, J., Takeshima, H., Yamamoto, S., and Ushio, Y. (1995). Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 72, 55-63.

89. Takano, S., Tsuboi, K., Tomono, Y., Mitsui, Y., and Nose, T. (2000). Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer 82, 1967-1973.

90. Perbal, B. (2004). CCN proteins: multifunctional signaling regulators. The Lancet 363, 62-64.

91. Perbal, B., Brigstock, D. R., and Lau, L. F. (2003). Report on the second international workshop on the CCN family of genes. BMA 56, 80-85.

92. Laurent, M., Martinerie, C., Thibout, H. et al. (2003). NOVH increases MMP3 expression and cell migration in glioblastoma cells via a PDGFR-a-dependent mechanism. FASEB J 17, 1919-1921.

93. Xie, D., Yin, D., Tong, X. et al. (2004a). Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and jß-catenin-TCF/Lef signaling pathways. Cancer Res 64, 1987-1996.

94. Jones, P. L., and Jones, F. S. (2000). Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 19, 581-596.

95. Giese, A., Loo, M. A., Norman, S. A., Treaurywala, S., and Berens, M. E. (1996). Contrasting migratory response of astrocytoma cells to tenascin mediated by different integrins. J Cell Sci 109, 2161-2168.

96. Golembieski, W. A., and Rempel, S. A. (2002). cDNA array analysis of SPARC-modulated changes in glioma gene expression. J Neurooncol 60, 213-226.

97. Golembieski, W. A., Ge, S., Nelson, K., Mikkelsen, T., and Rempel, S. A. (1999). Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev Neurosci 17, 463-472.

98. Schultz, C., Lemke, N., Ge, S., Golembieski, W. A., and Rempel, S. A. (2002). Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62, 6270-6277.

99. Rich, J. N., Shi, Q., Hjelmeland, M. et al. (2003). Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278, 15951-15957.

100. Iruela-Arispe, M. L., Vernon, R. B., Rudolf, J., and Sage, E. H. (1996). Type I collagen-deficient MOV-13 mice do not retain SPARC in the extracellular matrix: implications for fibroblast function. Dev Dyn 207, 171-183.

101. De Fraipont, F., Keramidas, M., El Atifi, M., Chambaz, E. M., Berger, F., and Fiege, J.-J. (2004). Expression of the thrombos-pondin 1 fragment 167-569 in C6 glioma cells stimulates tumorigenicity despite reduced neovascularization. Oncogene 23, 3642-3649.

102. Rao, J. S. (2003). Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3, 489-501.

103. Turk, V., Turk, B., and Turk, D. (2001). Lysosomal cysteine proteases: facts and opportunities. EMBO J 20, 4629-4633.

104. Rempel, S. A., Rosenblum, M. L., Mikkelsen, T. et al. (1994). Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54, 6027-6031.

105. Mikkelsen, T., Yan, P. S., Ho, K. L., Sameni, M., Sloane, B. F., and Rosenblum, M. L. Immunolocalization of cathepsin B in human glioma; implications for tumor invasion and angio-genesis. J Neurosurg 83, 285-290.

106. Sivaparvathi, M., Sawaya, R., Wang, S. W. et al. (1995). Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 13, 49-56.

107. Sivaparvathi, M., Sawaya, R., Chintala, S. K., Go, Y., Gokaslan, Z. L., and Rao, J. S. (1996a). Expression of cathepsin D during the progression of human gliomas. Neurosci Lett 208, 171-174.

108. Sivaparvathi, M., Sawaya, R., Gokaslan, Z. L., Chintala, S. K., Rao, J. S., and Chintala, K. S. (1996b). Expression and the role of cathepsin H in human glioma progression and invasion. Cancer Letters 104, 121-126.

109. Sivaparvathi, M., Yamamoto, M., Nicolson, G. L., Gokaslan, Z. L., and Rao, J. S. (1996c). Expression and immunohisto-chemical localization of cathepsin L during the progression of human gliomas. Clin Exp Metastasis 14, 27-34.

110. Flannery, T., Gibson, D., Mirakhur, M. et al. (2003). The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol 163, 175-182.

111. Levicar, N., Strojnik, T., Kos, J., Dewey, T. A., Pilkington, G. J., and Lah, T. T. (2002). Lysosomal enzymes, cathepsins in brain tumour invasion. J Neurooncol 58, 21-32.

112. Mohanam, S., Jasti, S. L., Kondrganti, S. R. et al. (2001). Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 20, 3663-3673.

113. Gondi, C. S., Lakka, S. S., Yanamandra, N. et al. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 64, 4069-4077.

114. Mercapide, J., Lopez De Cicco, R., Castresana J. S., Castresana J. S., and Klein-Szanto, A. J. (2003). Stromelysin-1/ matrix metalloproteinase 3 (MMP-3) expression accounts from invasive properties of human astrocytoma cell lines. Int J Cancer 106, 676-682.

115. Rao, J. S., Yamamoto, M., Mohanam, S. et al. (1996). Expression and localization of 92 kDa type IV collagenases/ gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 14, 21-28.

116. Forsyth, P. A., Wong, H., Laing, T. D. et al. (1999). Gelatinase-A (MMP-2), gelatinase B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79, 1828-1835.

117. Kondraganti, S., Mohanam, S., Chintala, S. K. et al. (2000). Selective suppression of matrix metalloproteinase-9 in human glioma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 60, 6851-6855.

118. Lakka, S. S., Rajan, M., Gondi, C. et al. (2002). Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 21, 8011-8019.

119. Hu, B., Guo, P., Fang, Q. et al. (2003) Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci USA 100, 8904-8909.

120. Lakka, S. S., Gondi, C. S., Yanamandra, N. et al. (2004). Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23, 4681-4689.

121. Lakka, S. S., Gondi, C. S., Yanamandra, N. et al. (2003). Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res 63, 2454-2461.

122. Mueller, M. M., Werbowetski, T., and del Maestro, R. F. (2003). Soluble factors involved in glioma invasion. Acta Neurochir (Wein) 145, 999-1008.

123. Vajkoczy, P., Menger, M. D., Goldbrunner, R. et al. (2000). Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int J Cancer 87, 261-268.

124. Harold-Mende, C., Steiner, H.-H., Andl, T. et al. (1999). Expression and functional role of VEGF receptors in human tumor cells. Lab Invest 79, 1573-1582.

125. Kupprion, C., Motamed, K., and Sage, E. H. (1998). SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 273, 29635-29640.

126. Moriyama, T., Kataoka, H., Koono, M., and Wakisak, S. (1999). Expression of hepatocyte growth factor/scatter factor and its receptor c-met in brain tumors: evidence for its role in progression of astrocytic tumors (review). Int J Med 3, 531-536.

127. Lamzus, K., Schmidt, N. O., Lin, J. et al. (1998). Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer 75, 19-28.

128. Lamzsus, K., Laterra, J., Westphal, M., and Rosen, E. M. (1999). Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Cancer 17, 517-530.

129. Hamasuna, R., Kataoka, H., Moriyama, T., Itoh, H., Seiki, M., and Koono, M. (1999). Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/ SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. Int J Cancer 82, 274-281.

130. Hirohito, Y., Hara, A., Murase, S., Nakano, S., Koono, M., and Wakisak, S. (2001). Expression of hepatocyte growth factor and matrix metalloproteinase-2 in human glioma. Brain Tumor Pathol 18, 7-12.

131. Moriyama, T., Kataoka, H., Hamasuna, R., Nakano, S., Koono, M., and Wakisak, S. (1999b). Upregulation of urokinase type plasminogen activator and u-PA receptor by hepatocyte growth factor/scatter factor stimulation in human glioma cells. Clin Exp Metastasis 17, 873-879.

132. Brockmann, M. A., Papadimitriou, A., Brandt, M., Fillbrandt, R., Westphal, M., and Lamzsus, K. (2003). Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 9, 4578-4585.

133. Rooprai, H. K., Rucklidge, G. J., Panou, C., and Pilkington, G. J. (2000). The effect of exogenous growth factors on matrix metalloproteinase secretion by human brain tumor cells. Br J Cancer 82, 52-55.

134. Kazsa, A., Kowanetz, M., Poslednik, K., Witek, B., Kordula, T., and Koj, A. (2001). Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of the plasminogen activation system in U737-MG astrocytoma cells. Cytokine 16, 187-190.

135. Koocheckpour, S., Merzak, A., and Pilkington, G. J. (1995). Extracellular matrix proteins inhibit proliferation, upregulate migration and induce morphological changes in human glioma cell lines. Eur J Cancer 31, 375-380.

136. Aguste, P., Gursel, D. B., Lemiere, S. et al. (2001). Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth both by angiogenesis-dependent and -independent mechanisms. Cancer Res 61, 1717-1726.

137. Mori, T., Tatsuya, A., Wakabayashi, Y. et al. (2000). Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-o^r basic fibroblast growth factor. J Neurooncol 46, 115-123.

138. Ovstrovsky, O., Berman, B., Gallagher, J. et al. (2002). Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem 277, 2444-2453.

139. Yamada, N., Kato, M., Yamashita, H. et al. (1995). Enhanced expression of transforming growth factor-beta and its type-I and -II receptors in human glioblastoma. Int J Cancer 62, 386-392.

140. Hamel, W., Westphal, M., Szonyi, E. et al. (1993). Neurotrophin gene expression by cell lines derived from human gliomas. J Neurosci Res 34, 147-157.

141. Wang, H., Wang, H., Shen, W. et al. (2003). Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-related genes. Cancer Res 63, 4315-4321.

142. Kahn, K. M., Falcone, D. J., and Kraemer, R. (2002). Nerve growth factor activation of Erk-1 and Erk-2 induced matrix metalloproteinase-9 expression in vascular smooth muscle cells. J Biol Chem 277, 2353-2359.

143. Zumkeller, W., and Westphal, M. (2001). The IGF/IGFBP system in CNS malignancy. J Clin Pathol Mol Pathol 54, 227-229.

144. Chakravarti, A., Zhai, G., Suzuki, Y. et al. (2004). The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22, 1926-1933.

145. Steinbach, J. P., Eisenmann, C., Klumpp, A., and Weller, M. (2004). Co-inhibition of epidermal growth factor receptor and type I insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem Biophys Res Commun 321, 524-530.

146. Miyake, K., Kimura, S., Nakanishi, M. et al. (2000). Transforming growth factor beta-1 stimulates contraction of human glioblastoma cell-mediated collagen lattice through enhanced alpha2 integrin expression. J Neuropathol Exp Neurol 59, 18-28.

147. Platten, M., Wick, W., Wild-Bode, C., Aulwurm, S., Dichgans, J., and Weller, M. (2000). Transforming growth factor beta-1 (TGF-betal) and TGF-beta2 promote glioma cell migration of alphaV-beta3 integrin expression. Biochem Biophy Res Commun 268, 607-611.

148. Neubauer, K., Kruger, M., Qondamatteo, F., Knittel, T., Siale, B., and Ramadori, G. (1999). Transforming growth factor-^1 stimulates he synthesis of basement membrane protein laminin, collagen type IV and entactin in rat liver sinusoidal endothelial cells. J Hepathol 31, 692-702.

149. Paulus, W., Baur, I., Huettner, C. et al. (1995). Effects of transforming growth factor-beta 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J Neuropathol Exp. Neurol 54, 236-244.

150. Wick, W., Platten, M., and Weller, M. (2001). Glioma cell invasion: regulation of metalloproteinase activity by TGF-ß. J Neurooncol 53, 177-185.

151. Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S., and Gladson, C. L. (1999). Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 5, 1587-1594.

152. Bello, L., Francolini, M., Marthyn, P. et al. (2001) av^3 and av^5 integrin expression in glioma periphery. Neurosurgery, 49, 380-390.

153. MacDonald, T. J., Taga, T., Shimada, H. et al. (2001). Preferential susceptibility of brain tumors to the antiangiogenic effects of an ov integrin antagonist. Neurosurgery 48, 151-157.

154. Chatterjee, S., Hiemstra Brite, K., and Matsumura, A. (2001). Induction of apoptosis of Integrin-expressing human prostate cancer cells by cyclic arg-gly-asp peptides. Clin Cancer Res 7, 3006-3011.

155. Nabors, L. B., Rosenfeld, S. S., Mikkelsen, T. et al. (2002). Phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas A236. Neuro-Oncology 4, 373.

156. Nabors, L. B., Rosenfeld, S. S., Mikkelsen, T. et al. (2004). NABTT 9911: A phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. TA-39. Neuro-Oncology 6, 379.

157. Shastry, A. N., Twieg, D. B., Mikkelsen, T. et al. (2004). Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging - quality and analysis results of a multi-institution phase I trial. J Magn Reson Imag 20, 913-922.

158. Burke, P. A., DeNardo, S. J., Miers, L. A., Lamborn, K. R., Matzku, S., and DeNardo G. L. (2002) Cilengitide targeting of v 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62, 4263-4272.

159. Mikkelsen, T., Nelson, K., and Brown, S. (2004). Cilengitide synergy with radiation therapy - molecular mechanisms. Proceedings of the AANS/CNS Section on Tumors Sixth Biennial Satellite Symposium. J Neuro-Oncol 69.

160. Koul, D., Bergh, S., Shen, R., and Yung, W. K. A. (2004). Targeting integrin linked kinase (ILK) pathway in human glioblastoma. ET-10. Neuro-oncology 6, 332.

161. Zalutsky, M. R., Moseley, R. P., Coakham, H. B., Coleman, R. E., and Bigner, D. D. (1989). Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49, 2807-2813.

162. Badruddoja, M. A., Reardon, D. A., Akabani, G. et al. (2004). Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. J Clin Oncol 22, 4S, 1569.

163. Groves, M. D., Puduvalli, V. K., Hess, K. R. et al. (2002). Phase II trial of temozolomide plus the matrix metalloprotei-nase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20, 1383-1388.

164. New, P., Mikkelsen, T., Phuphanich, S. et al. (2002). A phase I/II study of col-3 administered on a continuous oral schedule in patients with recurrent high grade glioma: preliminary results of the NABTT 9809 clinical trial A237. Neuro-Oncology 4, 373.

165. Wild-Bode, C., Weller, M., Rimner, A., Dichgans, J., and Wick, W. (2001). Sublethal irradiation promotes migration and invasiveness of glioma cells: Implications for radiotherapy of human glioblastoma. Cancer Res 61, 2744-2750.

166. Wick, W., Wick, A., Schulz, J. B., Dichgans, J., Rodemann, H. P., and Weller, M. (2002). Prevention of radiation-induced glioma cell invasion by Temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 62, 1915-1919.

PLATE 14.1 (Fig. 14.1)
PLATE 14.2 (Fig. 14.2)
Delicious Diabetic Recipes

Delicious Diabetic Recipes

This brilliant guide will teach you how to cook all those delicious recipes for people who have diabetes.

Get My Free Ebook

Post a comment